SCHEMBL5459316

SCHEMBL5459316

COCOc1cc(CO)cc(OCOC)c1C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.43
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
ABL1 P00519 1/20 0.38
NTRK1 P04629 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
IGF1R P08069 1/20 0.38
MET P08581 1/20 0.38
PDGFRB P09619 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
LTK P29376 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360406 0.85 KMT2A (0.45) ALOX15TSHRHSD17B10CYP3A4HTT
SCHEMBL14363320 0.83 GLO1 (0.43) EGFRTSHRHSD17B10CHEK1AURKA
SCHEMBL1515806 0.82 APP (0.47) ALOX15TSHRHSD17B10POLBCA12
SCHEMBL5455185 0.79 ALDH1A1 (0.42) EGFRCHEK1AURKADAPK3JAK2
SCHEMBL12553790 0.77 EGFR (0.39) EGFRCHEK1AURKADAPK3JAK2
SCHEMBL23202761 0.77 HSD17B10 (0.41) EGFRALOX15TSHRHSD17B10FYN
SCHEMBL5462929 0.76 EGFR (0.39) EGFRTSHRCHEK1AURKADAPK3
SCHEMBL5461990 0.76 EGFR (0.39) EGFRHSD17B10CHEK1AURKADAPK3
SCHEMBL12553846 0.75 GLO1 (0.47) EGFRCHEK1AURKADAPK3JAK2
SCHEMBL26874199 0.75 HSD17B10 (0.43) EGFRALOX15TSHRHSD17B10FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 EGFR 2482/4885ALOX15 1536/4885TSHR 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.